Phenotypic Characterization of Unclassified Pulmonary Hypertension.

IF 8.3 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Circulation: Heart Failure Pub Date : 2026-07-01 Epub Date: 2026-06-19 DOI:10.1161/CIRCHEARTFAILURE.125.014480
Yogesh N V Reddy, Robert P Frantz, Alexander C Egbe, William R Miranda, Aneesh K Asokan, Paul M Hassoun, Anna R Hemnes, Evelyn Horn, Jane A Leopold, Franz Rischard, Erika B Rosenzweig, Nicholas S Hill, Serpil C Erzurum, J Emanuel Finet, Monica Mukherjee, W H Wilson Tang, K Sreekumaran Nair, Barry A Borlaug
{"title":"Phenotypic Characterization of Unclassified Pulmonary Hypertension.","authors":"Yogesh N V Reddy, Robert P Frantz, Alexander C Egbe, William R Miranda, Aneesh K Asokan, Paul M Hassoun, Anna R Hemnes, Evelyn Horn, Jane A Leopold, Franz Rischard, Erika B Rosenzweig, Nicholas S Hill, Serpil C Erzurum, J Emanuel Finet, Monica Mukherjee, W H Wilson Tang, K Sreekumaran Nair, Barry A Borlaug","doi":"10.1161/CIRCHEARTFAILURE.125.014480","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Some symptomatic patients manifest pulmonary hypertension (PH), despite normal pulmonary vascular resistance and pulmonary artery wedge pressure-a condition termed unclassified PH. Although hypothesized to reflect increased flow as seen in congenital heart disease, broader clinical implications remain unknown.</p><p><strong>Methods: </strong>The current analysis included pulmonary vascular disease phenomics participants with either no PH or unclassified PH who underwent dynamic right heart catheterization and transpulmonary metabolomics. In a validation cohort, patients with no PH or unclassified PH underwent exercise right heart catheterization. In exploratory cohorts to understand the impact of increased flow, the prevalence of unclassified PH was assessed in (1) adult congenital heart disease and (2) high output heart failure.</p><p><strong>Results: </strong>The overall prevalence of unclassified PH in pulmonary vascular disease phenomics (n=1046) and the validation cohort (n=1202) was 7.8% (175/2248), which was comparable to the 6.6% (66/1005) prevalence in adult congenital heart disease (n=1005), and lower than high output heart failure (n=159, prevalence 14.5% [23/159]; <i>P</i>=0.006). Increased flow occurred in a minority of unclassified PH from both pulmonary vascular disease phenomics (28%; 15/53) and the validation cohort (11%; 13/122). Unclassified PH (n=53) was associated with greater adiposity, higher heart failure with preserved ejection fraction (HFpEF)-age, body mass index, atrial fibrillation score probability, and more left heart remodeling compared with those with no PH (n=216). Metabolomics revealed lower glycine metabolites in unclassified PH indicative of metabolic dysfunction. Left heart remodeling, quality of life, exercise capacity, and glycine levels were all abnormal in unclassified PH relative to healthy controls (n=96). In the validation cohort, pulmonary artery wedge pressure, pulmonary vascular resistance, and pulmonary artery compliance were subtly abnormal at rest in unclassified PH (n=122) compared with no PH (n=312). With exercise testing, 59% (72/122) with unclassified PH had exertional pulmonary artery wedge pressure elevation consistent with undiagnosed HFpEF.</p><p><strong>Conclusions: </strong>The presence of PH without obvious cause most often reflects subclinical left heart and metabolic dysfunction consistent with unrecognized early-stage HFpEF. Dynamic provocation during right heart catheterization can unmask unrecognized HFpEF in over half of unclassified PH, which may help guide appropriate initiation of proven HFpEF therapies to improve symptoms and functional status.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT02980887.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e014480"},"PeriodicalIF":8.3000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13286243/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCHEARTFAILURE.125.014480","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Some symptomatic patients manifest pulmonary hypertension (PH), despite normal pulmonary vascular resistance and pulmonary artery wedge pressure-a condition termed unclassified PH. Although hypothesized to reflect increased flow as seen in congenital heart disease, broader clinical implications remain unknown.

Methods: The current analysis included pulmonary vascular disease phenomics participants with either no PH or unclassified PH who underwent dynamic right heart catheterization and transpulmonary metabolomics. In a validation cohort, patients with no PH or unclassified PH underwent exercise right heart catheterization. In exploratory cohorts to understand the impact of increased flow, the prevalence of unclassified PH was assessed in (1) adult congenital heart disease and (2) high output heart failure.

Results: The overall prevalence of unclassified PH in pulmonary vascular disease phenomics (n=1046) and the validation cohort (n=1202) was 7.8% (175/2248), which was comparable to the 6.6% (66/1005) prevalence in adult congenital heart disease (n=1005), and lower than high output heart failure (n=159, prevalence 14.5% [23/159]; P=0.006). Increased flow occurred in a minority of unclassified PH from both pulmonary vascular disease phenomics (28%; 15/53) and the validation cohort (11%; 13/122). Unclassified PH (n=53) was associated with greater adiposity, higher heart failure with preserved ejection fraction (HFpEF)-age, body mass index, atrial fibrillation score probability, and more left heart remodeling compared with those with no PH (n=216). Metabolomics revealed lower glycine metabolites in unclassified PH indicative of metabolic dysfunction. Left heart remodeling, quality of life, exercise capacity, and glycine levels were all abnormal in unclassified PH relative to healthy controls (n=96). In the validation cohort, pulmonary artery wedge pressure, pulmonary vascular resistance, and pulmonary artery compliance were subtly abnormal at rest in unclassified PH (n=122) compared with no PH (n=312). With exercise testing, 59% (72/122) with unclassified PH had exertional pulmonary artery wedge pressure elevation consistent with undiagnosed HFpEF.

Conclusions: The presence of PH without obvious cause most often reflects subclinical left heart and metabolic dysfunction consistent with unrecognized early-stage HFpEF. Dynamic provocation during right heart catheterization can unmask unrecognized HFpEF in over half of unclassified PH, which may help guide appropriate initiation of proven HFpEF therapies to improve symptoms and functional status.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02980887.

未分类肺动脉高压的表型特征。
背景:一些有症状的患者表现为肺动脉高压(PH),尽管肺血管阻力和肺动脉楔压正常,这种情况被称为未分类PH。尽管假设反映了先天性心脏病中血流增加,但更广泛的临床意义尚不清楚。方法:目前的分析包括PVDOMICS参与者,无论是没有PH还是未分类的PH,他们都接受了动态右心导管插入术和经肺代谢组学。在一个验证队列中,没有PH或未分类PH的患者接受了运动性右心导管插入术。在了解血流增加影响的探索性队列中,评估了(1)成人先天性心脏病和(2)高输出量心力衰竭中未分类PH的患病率。结果:PVDOMICS (n=1046)和验证队列(n=1202)中未分类PH的总体患病率为7.8%(175/2248),与成人先天性心脏病(n=1005)的6.6%(66/1005)患病率相当,低于高输出量心力衰竭(n=159,患病率14.5% [23/159];P=0.006)。在PVDOMICS(28%; 15/53)和验证队列(11%;13/122)中,少数未分类的PH均出现血流增加。未分类PH (n=53)与未分类PH (n=216)的患者相比,与较高的肥胖、较高的心力衰竭(保留射血分数(HFpEF))、年龄、体重指数、房颤评分概率和更多的左心重构相关。代谢组学显示,未分类的PH值中甘氨酸代谢物较低,表明代谢功能障碍。与健康对照组相比,未分类PH组左心重构、生活质量、运动能力和甘氨酸水平均异常(n=96)。在验证队列中,未分类PH患者(n=122)与未分类PH患者(n=312)相比,肺动脉楔压、肺血管阻力和肺动脉顺应性在静止状态下轻微异常。通过运动测试,59%(72/122)未分类PH患者的肺动脉楔压升高与未诊断的HFpEF一致。结论:无明显原因的PH最常反映亚临床左心和代谢功能障碍,与未被识别的早期HFpEF一致。右心导管置管期间的动态刺激可以揭示一半以上未分类PH中未被识别的HFpEF,这可能有助于指导适当启动已证实的HFpEF治疗,以改善症状和功能状态。注册:网址:https://www.clinicaltrials.gov;唯一标识符:NCT02980887。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Circulation: Heart Failure
Circulation: Heart Failure 医学-心血管系统
CiteScore
12.90
自引率
3.10%
发文量
271
审稿时长
6-12 weeks
期刊介绍: Circulation: Heart Failure focuses on content related to heart failure, mechanical circulatory support, and heart transplant science and medicine. It considers studies conducted in humans or analyses of human data, as well as preclinical studies with direct clinical correlation or relevance. While primarily a clinical journal, it may publish novel basic and preclinical studies that significantly advance the field of heart failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书